These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37671163)

  • 21. Cryoablation combined with dual immune checkpoint blockade enhances antitumor efficacy in hepatocellular carcinoma model mice.
    Gu J; Yu Z; Tang X; Chen W; Deng X; Zhu X
    Int J Hyperthermia; 2024; 41(1):2373319. PubMed ID: 38955354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining local cryoablation with PD-L1 blockade synergistically eradicates established murine lung cancer by modulating mitochondrial in PD-1+CD8+ T cell.
    Zhai JW; Lv LL; Wu JJ; Zhang YX; Shen Y; Qu QX; Chen C
    Immunol Lett; 2023 Nov; 263():61-69. PubMed ID: 37805094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer.
    Sardela de Miranda F; Castro M; Remmert N; Singh SP; Layeequr Rahman R; Melkus MW
    Front Immunol; 2023; 14():1258873. PubMed ID: 37860001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy.
    Yu Z; Wang D; Qi Y; Liu J; Zhou T; Rao W; Hu K
    Mater Horiz; 2023 May; 10(5):1661-1677. PubMed ID: 36880811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy.
    Adam LC; Raja J; Ludwig JM; Adeniran A; Gettinger SN; Kim HS
    J Immunother Cancer; 2018 Dec; 6(1):147. PubMed ID: 30541627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes.
    Takada M; Toi M
    Int J Clin Oncol; 2019 Jun; 24(6):608-613. PubMed ID: 30982153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer immunotherapy using tumor cryoablation.
    Sidana A
    Immunotherapy; 2014; 6(1):85-93. PubMed ID: 24341887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cryo-immunologic effect: A therapeutic advance in the treatment of glioblastomas?
    Cebula H; Noel G; Garnon J; Todeschi J; Burckel H; de Mathelin M; Gangi A; Proust F
    Neurochirurgie; 2020 Dec; 66(6):455-460. PubMed ID: 33045247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The application effect of percutaneous cryoablation for the stage IIIB/IV advanced non-small-cell lung cancer after the failure of chemoradiotherapy.
    Gao W; Guo Z; Shu S; Xing W; Zhang W; Yang X
    Asian J Surg; 2018 Nov; 41(6):530-536. PubMed ID: 29609955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes following cryoablation of stage IA non-small cell lung cancer in patients with and without interstitial lung disease: A retrospective single-center cohort study.
    Sänger JA; Graur A; Tahir I; Price MC; Keane FK; Lanuti M; Sharma A; Fintelmann FJ
    Lung Cancer; 2023 Jul; 181():107231. PubMed ID: 37172368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cryoablation combined with a clinical Chinese medicine for the treatment of lung cancer.
    Wang X; Hou Y; Liu Q; Zhou T; Rao W
    Cryobiology; 2023 Sep; 112():104559. PubMed ID: 37451669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
    Popat S; Grohé C; Corral J; Reck M; Novello S; Gottfried M; Radonjic D; Kaiser R
    Lung Cancer; 2020 Jun; 144():76-84. PubMed ID: 32387684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percutaneous comprehensive cryoablation for metastatic esophageal cancer after failure of radical surgery.
    Jiongyuan X; Lizhi N; Feng M; Shupeng L; Yin L; Mengtian L; Jianying Z; Fei Y; Jibing C; Jialiang L; Kecheng X
    Cryobiology; 2013 Dec; 67(3):363-8. PubMed ID: 24383130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Memmott RM; Wolfe AR; Carbone DP; Williams TM
    J Thorac Oncol; 2021 Jul; 16(7):1086-1098. PubMed ID: 33845212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cryoablation Does Not Significantly Contribute to Systemic Effector Immune Responses in a Poorly Immunogenic B16F10 Melanoma Model.
    Yakkala C; Corria-Osorio J; Kandalaft L; Denys A; Koppolu B; Duran R
    Clin Cancer Res; 2024 Sep; 30(18):4190-4200. PubMed ID: 39024020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
    Yakkala C; Chiang CL; Kandalaft L; Denys A; Duran R
    Front Immunol; 2019; 10():2283. PubMed ID: 31608067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.